-
1
-
-
0035235736
-
Mitotic kinases as regulators of cell division and its checkpoints
-
Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol (2001) 2(1):21-32.
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, Issue.1
, pp. 21-32
-
-
Nigg, E.A.1
-
2
-
-
0242551545
-
The cellular geography of Aurora kinases
-
An excellent review on the biology of Aurora kinases, ··
-
Carmena M, Earnshaw WC: The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol (2003) 4(11):842-854. ·· An excellent review on the biology of Aurora kinases.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, Issue.11
, pp. 842-854
-
-
Carmena, M.1
Earnshaw, W.C.2
-
3
-
-
0033106222
-
The conserved protein kinase Ipl1 regulates microtubule binding to kinetochores in budding yeast
-
Biggins S, Severin FF, Bhalla N, Sassoon I, Hyman AA, Murray AW: The conserved protein kinase Ipl1 regulates microtubule binding to kinetochores in budding yeast. Genes Dev (1999) 13(5):532-544.
-
(1999)
Genes Dev
, vol.13
, Issue.5
, pp. 532-544
-
-
Biggins, S.1
Severin, F.F.2
Bhalla, N.3
Sassoon, I.4
Hyman, A.A.5
Murray, A.W.6
-
4
-
-
11144225241
-
-
Marumoto T, Zhang D, Saya H: Aurora-A - A guardian of poles.Nat Rev Cancer (2005) 5(1):42-50. ·· A good introduction to the biology of Aurora A.
-
Marumoto T, Zhang D, Saya H: Aurora-A - A guardian of poles.Nat Rev Cancer (2005) 5(1):42-50. ·· A good introduction to the biology of Aurora A.
-
-
-
-
5
-
-
23744503085
-
Aurora kinases: Shining lights on the therapeutic horizon?
-
Andrews PD: Aurora kinases: Shining lights on the therapeutic horizon? Oncogene (2005) 24(32):5005-5015.
-
(2005)
Oncogene
, vol.24
, Issue.32
, pp. 5005-5015
-
-
Andrews, P.D.1
-
6
-
-
0032100685
-
A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers
-
·· Describes the mammalian Aurora A and Aurora B kinases and their overexpression in human colorectal tumors. Provides the first evidence that the overexpression of Aurora A is linked to cancer
-
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS et al: A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 17(11):3052-3065. ·· Describes the mammalian Aurora A and Aurora B kinases and their overexpression in human colorectal tumors. Provides the first evidence that the overexpression of Aurora A is linked to cancer.
-
(1998)
EMBO J
, vol.17
, Issue.11
, pp. 3052-3065
-
-
Bischoff, J.R.1
Anderson, L.2
Zhu, Y.3
Mossie, K.4
Ng, L.5
Souza, B.6
Schryver, B.7
Flanagan, P.8
Clairvoyant, F.9
Ginther, C.10
Chan, C.S.11
-
7
-
-
0033548619
-
Cell cycle-dependent expression and centrosome localization of a third human Aurora/Ipl1-related protein kinase, AIK3
-
Kimura M, Matsuda Y, Yoshioka T, Okano Y: Cell cycle-dependent expression and centrosome localization of a third human Aurora/Ipl1-related protein kinase, AIK3. J Biol Chem (1999) 274(11):7334-7340.
-
(1999)
J Biol Chem
, vol.274
, Issue.11
, pp. 7334-7340
-
-
Kimura, M.1
Matsuda, Y.2
Yoshioka, T.3
Okano, Y.4
-
8
-
-
8744313990
-
Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C
-
Li X, Sakashita G, Matsuzaki H, Sugimoto K, Kimura K, Hanaoka F, Taniguchi H, Furukawa K, Urano T: Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem (2004) 279(45):47201-47211.
-
(2004)
J Biol Chem
, vol.279
, Issue.45
, pp. 47201-47211
-
-
Li, X.1
Sakashita, G.2
Matsuzaki, H.3
Sugimoto, K.4
Kimura, K.5
Hanaoka, F.6
Taniguchi, H.7
Furukawa, K.8
Urano, T.9
-
9
-
-
19944394833
-
Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells
-
Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, Okano Y, Tatsuka M, Suzuki F, Nigg EA, Earnshaw WC et al: Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton (2004) 59(4):249-263.
-
(2004)
Cell Motil Cytoskeleton
, vol.59
, Issue.4
, pp. 249-263
-
-
Sasai, K.1
Katayama, H.2
Stenoien, D.L.3
Fujii, S.4
Honda, R.5
Kimura, M.6
Okano, Y.7
Tatsuka, M.8
Suzuki, F.9
Nigg, E.A.10
Earnshaw, W.C.11
-
10
-
-
33847194971
-
Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis
-
Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Höög C, van Duin M, Gossen JA, Sassone-Corsi P: Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol (2007) 21(3):726-739.
-
(2007)
Mol Endocrinol
, vol.21
, Issue.3
, pp. 726-739
-
-
Kimmins, S.1
Crosio, C.2
Kotaja, N.3
Hirayama, J.4
Monaco, L.5
Höög, C.6
van Duin, M.7
Gossen, J.A.8
Sassone-Corsi, P.9
-
11
-
-
0038341158
-
The Aurora kinases: Role in cell transformation and tumorigenesis
-
Katayama H, Brinkley WR, Sen S: The Aurora kinases: Role in cell transformation and tumorigenesis. Cancer Metastasis Rev(2003) 22(4):451-464.
-
(2003)
Cancer Metastasis Rev
, vol.22
, Issue.4
, pp. 451-464
-
-
Katayama, H.1
Brinkley, W.R.2
Sen, S.3
-
12
-
-
0842281498
-
Aurora kinases link chromosome segregation and cell division to cancer susceptibility
-
Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility.Curr Opin Genet Dev (2004) 14(1):29-36.
-
(2004)
Curr Opin Genet Dev
, vol.14
, Issue.1
, pp. 29-36
-
-
Meraldi, P.1
Honda, R.2
Nigg, E.A.3
-
13
-
-
10344236486
-
Aurora-kinase inhibitors as anticancer agents
-
A comprehensive review of the most well-characterized Aurora kinase inhibitors, ·
-
Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer (2004) 4(12):927-936. · A comprehensive review of the most well-characterized Aurora kinase inhibitors.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.12
, pp. 927-936
-
-
Keen, N.1
Taylor, S.2
-
14
-
-
33845743957
-
Aurora kinases: New targets for cancer therapy
-
Carvajal RD, Tse A, Schwartz GK: Aurora kinases: New targets for cancer therapy. Clin Cancer Res (2006) 12(23):6869-6875.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.23
, pp. 6869-6875
-
-
Carvajal, R.D.1
Tse, A.2
Schwartz, G.K.3
-
15
-
-
47949108203
-
Aurora kinases and their inhibitors: More than one target and one drug
-
Carpinelli P, Moll J: Aurora kinases and their inhibitors: More than one target and one drug. Adv Exp Med Biol (2008) 610:54-73.
-
(2008)
Adv Exp Med Biol
, vol.610
, pp. 54-73
-
-
Carpinelli, P.1
Moll, J.2
-
16
-
-
41549122837
-
Aurora kinases as anticancer drug targets
-
Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR: Aurora kinases as anticancer drug targets.Clin Cancer Res (2008) 14(6):1639-1648.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.6
, pp. 1639-1648
-
-
Gautschi, O.1
Heighway, J.2
Mack, P.C.3
Purnell, P.R.4
Lara Jr, P.N.5
Gandara, D.R.6
-
18
-
-
35948952013
-
DNA replication licensing factors and Aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma
-
Kulkarni AA, Loddo M, Leo E, Rashid M, Eward KL, Fanshawe TR, Butcher J, Frost A, Ledermann JA, Williams GH, Stoeber K: DNA replication licensing factors and Aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res (2007) 13(20):6153-6161.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.20
, pp. 6153-6161
-
-
Kulkarni, A.A.1
Loddo, M.2
Leo, E.3
Rashid, M.4
Eward, K.L.5
Fanshawe, T.R.6
Butcher, J.7
Frost, A.8
Ledermann, J.A.9
Williams, G.H.10
Stoeber, K.11
-
19
-
-
33749002867
-
Aurora sheds light on head and neck squamous cell carcinoma
-
Han H, Von Hoff DD: Aurora sheds light on head and neck squamous cell carcinoma. Clin Cancer Res (2006) 12(17): 5003-5004.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.17
, pp. 5003-5004
-
-
Han, H.1
Von Hoff, D.D.2
-
20
-
-
38949203768
-
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from Aurora kinase inhibition
-
Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R: The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from Aurora kinase inhibition.Blood (2008) 111(3):1603-1609.
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1603-1609
-
-
Chng, W.J.1
Braggio, E.2
Mulligan, G.3
Bryant, B.4
Remstein, E.5
Valdez, R.6
Dogan, A.7
Fonseca, R.8
-
21
-
-
34547109084
-
Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients
-
Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK: Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res (2007) 13(14):4098-4104.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.14
, pp. 4098-4104
-
-
Landen Jr, C.N.1
Lin, Y.G.2
Immaneni, A.3
Deavers, M.T.4
Merritt, W.M.5
Spannuth, W.A.6
Bodurka, D.C.7
Gershenson, D.M.8
Brinkley, W.R.9
Sood, A.K.10
-
22
-
-
33746080016
-
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity
-
Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R et al: PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res (2006) 12(13):4080-4089.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.13
, pp. 4080-4089
-
-
Soncini, C.1
Carpinelli, P.2
Gianellini, L.3
Fancelli, D.4
Vianello, P.5
Rusconi, L.6
Storici, P.7
Zugnoni, P.8
Pesenti, E.9
Croci, V.10
Ceruti, R.11
-
23
-
-
4444239881
-
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer
-
Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ: The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 3(4):451-457.
-
(2004)
Mol Cancer Ther
, vol.3
, Issue.4
, pp. 451-457
-
-
Rojanala, S.1
Han, H.2
Muñoz, R.M.3
Browne, W.4
Nagle, R.5
Von Hoff, D.D.6
Bearss, D.J.7
-
24
-
-
0028938482
-
Mutations in Aurora prevent centrosome separation leading to the formation of monopolar spindles
-
First report describing the Aurora kinase and its functions in Drosophila, ··
-
Glover DM, Leibowitz MH, McLean DA, Parry H: Mutations in Aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 81(1):95-105. ·· First report describing the Aurora kinase and its functions in Drosophila.
-
(1995)
Cell
, vol.81
, Issue.1
, pp. 95-105
-
-
Glover, D.M.1
Leibowitz, M.H.2
McLean, D.A.3
Parry, H.4
-
25
-
-
0038746733
-
The small molecule hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
-
Describes the first small-molecule Aurora kinase inhibitor, and the molecular and phenotypic effects of inhibition of this kinase, ·
-
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM: The small molecule hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol (2003) 161(2):281-294. · Describes the first small-molecule Aurora kinase inhibitor, and the molecular and phenotypic effects of inhibition of this kinase.
-
(2003)
J Cell Biol
, vol.161
, Issue.2
, pp. 281-294
-
-
Hauf, S.1
Cole, R.W.2
LaTerra, S.3
Zimmer, C.4
Schnapp, G.5
Walter, R.6
Heckel, A.7
van Meel, J.8
Rieder, C.L.9
Peters, J.M.10
-
26
-
-
66549124940
-
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time
-
Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, Newlander K, Dhanak D, Adams J, Patrick D, Copeland RA et al: Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time. Biochem J(2009) 420(2):259-265.
-
(2009)
Biochem J
, vol.420
, Issue.2
, pp. 259-265
-
-
Anderson, K.1
Lai, Z.2
McDonald, O.B.3
Stuart, J.D.4
Nartey, E.N.5
Hardwicke, M.A.6
Newlander, K.7
Dhanak, D.8
Adams, J.9
Patrick, D.10
Copeland, R.A.11
-
27
-
-
65649112968
-
Biochemical characterisation of GSK1070916, a potent and selective inhibitor of Aurora B kinase with an extremely slow off-rate
-
Abs
-
Yang L, Anderson K, Hardwick MA, Silva D, Newlander K, McDonald OB, Adams J, Patrick D, Tummino PJ, Copeland RA, Lai Z: Biochemical characterisation of GSK1070916, a potent and selective inhibitor of Aurora B kinase with an extremely slow off-rate. Proceedings of the AACR Annual Meeting (2008) 99: Abs 5649.
-
(2008)
Proceedings of the AACR Annual Meeting
, vol.99
, pp. 5649
-
-
Yang, L.1
Anderson, K.2
Hardwick, M.A.3
Silva, D.4
Newlander, K.5
McDonald, O.B.6
Adams, J.7
Patrick, D.8
Tummino, P.J.9
Copeland, R.A.10
Lai, Z.11
-
28
-
-
37549027270
-
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity
-
Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S et al: Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther (2007) 6(12 Pt 1):3147-3157.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.12 PART 1
, pp. 3147-3157
-
-
Chan, F.1
Sun, C.2
Perumal, M.3
Nguyen, Q.D.4
Bavetsias, V.5
McDonald, E.6
Martins, V.7
Wilsher, N.E.8
Raynaud, F.I.9
Valenti, M.10
Eccles, S.11
-
29
-
-
67649940506
-
-
Gavai A, Norris D, Trainor G, Vite G, Zhao Y, Vyas D, Tokarski J, Han W, Wong T, Rupnow B: Pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Aurora kinases. EJC Supplements (2008) 6(12): 93-94.
-
Gavai A, Norris D, Trainor G, Vite G, Zhao Y, Vyas D, Tokarski J, Han W, Wong T, Rupnow B: Pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Aurora kinases. EJC Supplements (2008) 6(12): 93-94.
-
-
-
-
30
-
-
67649905538
-
-
Aurora kinase project/CTK110 series: Cetek Corporation, Marlborough, MA, USA (2009). www.cetek.com/ctk110.html
-
Aurora kinase project/CTK110 series: Cetek Corporation, Marlborough, MA, USA (2009). www.cetek.com/ctk110.html
-
-
-
-
31
-
-
67649905537
-
Pharmacokinetics of MP-529, a selective Aurora A kinase inhibitor, in a novel subcutaneous delivery system
-
Abs
-
Joshi R, Kanekal S, Tang C, Sadikin S, Inloes R, Shi C, Severson P, Lamb J, Bearss J, Bearss D, Redkar S: Pharmacokinetics of MP-529, a selective Aurora A kinase inhibitor, in a novel subcutaneous delivery system. Proceedings of the AACR Annual Meeting (2008) 99: Abs 5729.
-
(2008)
Proceedings of the AACR Annual Meeting
, vol.99
, pp. 5729
-
-
Joshi, R.1
Kanekal, S.2
Tang, C.3
Sadikin, S.4
Inloes, R.5
Shi, C.6
Severson, P.7
Lamb, J.8
Bearss, J.9
Bearss, D.10
Redkar, S.11
-
32
-
-
33845367377
-
-
Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P et al: 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem (2006) 49(24):7247-7251. ·· Describes the first small-molecule inhibitor of Aurora kinase, danusertib, which has entered clinical development.
-
Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P et al: 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem (2006) 49(24):7247-7251. ·· Describes the first small-molecule inhibitor of Aurora kinase, danusertib, which has entered clinical development.
-
-
-
-
33
-
-
37549071104
-
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
-
Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L et al: PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.Mol Cancer Ther (2007) 6(12 Pt 1):3158-3168.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.12 PART 1
, pp. 3158-3168
-
-
Carpinelli, P.1
Ceruti, R.2
Giorgini, M.L.3
Cappella, P.4
Gianellini, L.5
Croci, V.6
Degrassi, A.7
Texido, G.8
Rocchetti, M.9
Vianello, P.10
Rusconi, L.11
-
34
-
-
34548548332
-
Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358
-
Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A et al: Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358. Cancer Res (2007) 67(17):7987-7990.
-
(2007)
Cancer Res
, vol.67
, Issue.17
, pp. 7987-7990
-
-
Modugno, M.1
Casale, E.2
Soncini, C.3
Rosettani, P.4
Colombo, R.5
Lupi, R.6
Rusconi, L.7
Fancelli, D.8
Carpinelli, P.9
Cameron, A.D.10
Isacchi, A.11
-
35
-
-
43249111278
-
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
-
Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH: Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood (2008) 111(8):4355-4364.
-
(2008)
Blood
, vol.111
, Issue.8
, pp. 4355-4364
-
-
Gontarewicz, A.1
Balabanov, S.2
Keller, G.3
Colombo, R.4
Graziano, A.5
Pesenti, E.6
Benten, D.7
Bokemeyer, C.8
Fiedler, W.9
Moll, J.10
Brümmendorf, T.H.11
-
36
-
-
0038780904
-
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies
-
Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C: Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia (2003) 17(7):1211-1262.
-
(2003)
Leukemia
, vol.17
, Issue.7
, pp. 1211-1262
-
-
Clarkson, B.1
Strife, A.2
Wisniewski, D.3
Lambek, C.L.4
Liu, C.5
-
37
-
-
0025728772
-
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction
-
Maurer J, Janssen JW, Thiel E, van Denderen J, Ludwig WD, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A et al: Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 337(8749):1055-1058.
-
(1991)
Lancet
, vol.337
, Issue.8749
, pp. 1055-1058
-
-
Maurer, J.1
Janssen, J.W.2
Thiel, E.3
van Denderen, J.4
Ludwig, W.D.5
Aydemir, U.6
Heinze, B.7
Fonatsch, C.8
Harbott, J.9
Reiter, A.10
-
38
-
-
0031931662
-
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: Correlation with clinicopathological features
-
Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA: RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: Correlation with clinicopathological features. Clin Cancer Res (1998) 4(1): 223-228.
-
(1998)
Clin Cancer Res
, vol.4
, Issue.1
, pp. 223-228
-
-
Bongarzone, I.1
Vigneri, P.2
Mariani, L.3
Collini, P.4
Pilotti, S.5
Pierotti, M.A.6
-
39
-
-
0031872458
-
Cell cycle-independent death of prostate adenocarcinoma is induced by the Trk tyrosine kinase inhibitor CEP-751 (KT6587)
-
Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D et al: Cell cycle-independent death of prostate adenocarcinoma is induced by the Trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res (1998) 4(8):1887-1898.
-
(1998)
Clin Cancer Res
, vol.4
, Issue.8
, pp. 1887-1898
-
-
Dionne, C.A.1
Camoratto, A.M.2
Jani, J.P.3
Emerson, E.4
Neff, N.5
Vaught, J.L.6
Murakata, C.7
Djakiew, D.8
Lamb, J.9
Bova, S.10
George, D.11
-
40
-
-
33749993417
-
The consensus coding sequences of human breast and colorectal cancers
-
Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S et al: The consensus coding sequences of human breast and colorectal cancers. Science (2006) 314(5797):268-274.
-
(2006)
Science
, vol.314
, Issue.5797
, pp. 268-274
-
-
Sjöblom, T.1
Jones, S.2
Wood, L.D.3
Parsons, D.W.4
Lin, J.5
Barber, T.D.6
Mandelker, D.7
Leary, R.J.8
Ptak, J.9
Silliman, N.10
Szabo, S.11
-
41
-
-
0036142218
-
Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases
-
Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P: Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol (2002) 22(3):874-885.
-
(2002)
Mol Cell Biol
, vol.22
, Issue.3
, pp. 874-885
-
-
Crosio, C.1
Fimia, G.M.2
Loury, R.3
Kimura, M.4
Okano, Y.5
Zhou, H.6
Sen, S.7
Allis, C.D.8
Sassone-Corsi, P.9
-
42
-
-
39049166077
-
Aurora kinase inhibitors: Identification and preclinical validation of their biomarkers
-
Carpinelli P, Moll J: Aurora kinase inhibitors: Identification and preclinical validation of their biomarkers. Expert Opin Ther Targets (2008) 12(1):69-80.
-
(2008)
Expert Opin Ther Targets
, vol.12
, Issue.1
, pp. 69-80
-
-
Carpinelli, P.1
Moll, J.2
-
43
-
-
73549111210
-
A phase I pharmacokinetic and pharmacodynamic study of the Aurora kinase inhibitor PHA-739358 in patients with advanced or metastatic solid tumors
-
in press
-
Steeghs N, Eskens FAL, Gelderblom H, Verweij J, Nortier JWR, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B et al: A phase I pharmacokinetic and pharmacodynamic study of the Aurora kinase inhibitor PHA-739358 in patients with advanced or metastatic solid tumors. J Clin Oncol (2009): in press.
-
(2009)
J Clin Oncol
-
-
Steeghs, N.1
Eskens, F.A.L.2
Gelderblom, H.3
Verweij, J.4
Nortier, J.W.R.5
Ouwerkerk, J.6
van Noort, C.7
Mariani, M.8
Spinelli, R.9
Carpinelli, P.10
Laffranchi, B.11
-
44
-
-
59349101062
-
HA: Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors
-
Abs
-
Cohen B, Jones SF, von Mehren M, Cheng J, Spiegel DM, Laffranchi B, Mariani M, Spinelli R, Magazzu D, and A. Burris HA: Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. J Clin Oncol (2008) 26:Abs 2520.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2520
-
-
Cohen, B.1
Jones, S.F.2
von Mehren, M.3
Cheng, J.4
Spiegel, D.M.5
Laffranchi, B.6
Mariani, M.7
Spinelli, R.8
Magazzu, D.9
Burris, A.10
-
45
-
-
61849136570
-
PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL
-
Abs 1030
-
Paquette RL, Shah NP, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti M, Fiocchi C, Comis S, Capolongo L, Laffranchi B: PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood (2007) 110(1): Abs 1030.
-
(2007)
Blood
, vol.110
, Issue.1
-
-
Paquette, R.L.1
Shah, N.P.2
Sawyers, C.L.3
Martinelli, G.4
John, N.5
Chalukya, M.6
Rocchetti, M.7
Fiocchi, C.8
Comis, S.9
Capolongo, L.10
Laffranchi, B.11
-
46
-
-
2342639645
-
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
-
The first report of the activity of an Aurora kinase inhibitor (VX-680) in animal tumor models, ·
-
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 10(3): 262-267. · The first report of the activity of an Aurora kinase inhibitor (VX-680) in animal tumor models.
-
(2004)
Nat Med
, vol.10
, Issue.3
, pp. 262-267
-
-
Harrington, E.A.1
Bebbington, D.2
Moore, J.3
Rasmussen, R.K.4
Ajose-Adeogun, A.O.5
Nakayama, T.6
Graham, J.A.7
Demur, C.8
Hercend, T.9
Diu-Hercend, A.10
Su, M.11
-
47
-
-
31644438945
-
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680
-
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL et al: Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res (2006) 66(2):1007-1014.
-
(2006)
Cancer Res
, vol.66
, Issue.2
, pp. 1007-1014
-
-
Young, M.A.1
Shah, N.P.2
Chao, L.H.3
Seeliger, M.4
Milanov, Z.V.5
Biggs 3rd, W.H.6
Treiber, D.K.7
Patel, H.K.8
Zarrinkar, P.P.9
Lockhart, D.J.10
Sawyers, C.L.11
-
48
-
-
67649897709
-
-
Rubin EH, Shapiro GI, Stein MN, Watson P, Bergstrom D, Xiao A, Clark JB, Freedman SJ, Eder JP: A phase I clinical and pharmacokinetic (PK) trial of the Aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol (2006) 24(June 20 Suppl):Abs 3009.
-
Rubin EH, Shapiro GI, Stein MN, Watson P, Bergstrom D, Xiao A, Clark JB, Freedman SJ, Eder JP: A phase I clinical and pharmacokinetic (PK) trial of the Aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol (2006) 24(June 20 Suppl):Abs 3009.
-
-
-
-
49
-
-
33846878294
-
New blood cancer therapies under study
-
Hampton T: New blood cancer therapies under study.J Am Med Assoc (2007) 297(5):457-458.
-
(2007)
J Am Med Assoc
, vol.297
, Issue.5
, pp. 457-458
-
-
Hampton, T.1
-
50
-
-
33846240316
-
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
-
Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2007) 109(2):500-502.
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 500-502
-
-
Giles, F.J.1
Cortes, J.2
Jones, D.3
Bergstrom, D.4
Kantarjian, H.5
Freedman, S.J.6
-
51
-
-
33947174540
-
-
Vertex Pharmaceuticals Inc: Vertex's collaborator Merck suspends patient enrollment in clinical trials of MK-0457 (VX-680) pending full analysis of clinical data, November 20
-
Vertex Pharmaceuticals Inc: Vertex's collaborator Merck suspends patient enrollment in clinical trials of MK-0457 (VX-680) pending full analysis of clinical data. Press Release(2007): November 20.
-
(2007)
Press Release
-
-
-
52
-
-
34247603906
-
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase
-
The first report of a selective Aurora B kinase inhibitor, AZD-1152, that entered clinical trials, ·
-
Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T et al: Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem (2007) 50(9):2213-2224. · The first report of a selective Aurora B kinase inhibitor, AZD-1152, that entered clinical trials.
-
(2007)
J Med Chem
, vol.50
, Issue.9
, pp. 2213-2224
-
-
Mortlock, A.A.1
Foote, K.M.2
Heron, N.M.3
Jung, F.H.4
Pasquet, G.5
Lohmann, J.J.6
Warin, N.7
Renaud, F.8
De Savi, C.9
Roberts, N.J.10
Johnson, T.11
-
53
-
-
34250739960
-
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
-
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF et al: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.Clin Cancer Res (2007) 13(12):3682-3688.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.12
, pp. 3682-3688
-
-
Wilkinson, R.W.1
Odedra, R.2
Heaton, S.P.3
Wedge, S.R.4
Keen, N.J.5
Crafter, C.6
Foster, J.R.7
Brady, M.C.8
Bigley, A.9
Brown, E.10
Byth, K.F.11
-
54
-
-
67649895327
-
-
Schellens JH, Boss D, Witteveen PO, Zandvliet A, Beijnen JH, Voogel-Fuchs M, Morris C, Wilson D, Voest EE: Phase I and pharmacological study of the novel Aurora kinase inhibitor AZD1152. J Clin Oncol (2006) 24(18S):3008.
-
Schellens JH, Boss D, Witteveen PO, Zandvliet A, Beijnen JH, Voogel-Fuchs M, Morris C, Wilson D, Voest EE: Phase I and pharmacological study of the novel Aurora kinase inhibitor AZD1152. J Clin Oncol (2006) 24(18S):3008.
-
-
-
-
55
-
-
34247259822
-
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
-
Describes the in vitro and in vivo characterization of MLN-8054, the first selective Aurora A inhibitor to undergo clinical development, ·
-
Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET et al: Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA (2007) 104(10):4106-4111. · Describes the in vitro and in vivo characterization of MLN-8054, the first selective Aurora A inhibitor to undergo clinical development.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.10
, pp. 4106-4111
-
-
Manfredi, M.G.1
Ecsedy, J.A.2
Meetze, K.A.3
Balani, S.K.4
Burenkova, O.5
Chen, W.6
Galvin, K.M.7
Hoar, K.M.8
Huck, J.J.9
LeRoy, P.J.10
Ray, E.T.11
-
56
-
-
33845600990
-
Preclinical pharmacodynamic studies of Aurora A inhibition by MLN8054
-
Galvin KM, Huck J, Burenkova O, Burke K, Bowman D, Shinde V, Stringer B, Zhang M, Manfredi M, Meetze K: Preclinical pharmacodynamic studies of Aurora A inhibition by MLN8054. J Clin Oncol (2006) 24(18S):13059.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
, pp. 13059
-
-
Galvin, K.M.1
Huck, J.2
Burenkova, O.3
Burke, K.4
Bowman, D.5
Shinde, V.6
Stringer, B.7
Zhang, M.8
Manfredi, M.9
Meetze, K.10
-
57
-
-
67649931895
-
MLN8054, a selective inhibitor of Aurora A kinase: Final results of a phase I clinical trial
-
Cervantes A, Macarulla T, Roselló S, Rodríguez-Braun E, Baselga J, Tabernero J, Liu H, Chakravarty A, Bowman D, Eton O: MLN8054, a selective inhibitor of Aurora A kinase: Final results of a phase I clinical trial. EJC Supplements (2008) 6(12):90.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 90
-
-
Cervantes, A.1
Macarulla, T.2
Roselló, S.3
Rodríguez-Braun, E.4
Baselga, J.5
Tabernero, J.6
Liu, H.7
Chakravarty, A.8
Bowman, D.9
Eton, O.10
-
58
-
-
67649913231
-
Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase
-
Dees E, Infante JR, Cohen RB, O'Neil B, Burris H, von Mehren M, Gray G, Galvin K, Manfredi M, Eton O: Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase. EJC Supplements (2008) 6(12):91.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 91
-
-
Dees, E.1
Infante, J.R.2
Cohen, R.B.3
O'Neil, B.4
Burris, H.5
von Mehren, M.6
Gray, G.7
Galvin, K.8
Manfredi, M.9
Eton, O.10
-
59
-
-
65649086159
-
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
-
Infante J, Dees EC, Cohen RB, Burris H, O'Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. EJC Supplements (2008) 6(12):90-91.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 90-91
-
-
Infante, J.1
Dees, E.C.2
Cohen, R.B.3
Burris, H.4
O'Neil, B.5
Murphy, P.6
Lee, Y.7
Pappas, J.8
Ecsedy, J.A.9
Eton, O.10
-
60
-
-
60549088370
-
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity
-
Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M et al: Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J Med Chem (2009) 52(2):379-388.
-
(2009)
J Med Chem
, vol.52
, Issue.2
, pp. 379-388
-
-
Howard, S.1
Berdini, V.2
Boulstridge, J.A.3
Carr, M.G.4
Cross, D.M.5
Curry, J.6
Devine, L.A.7
Early, T.R.8
Fazal, L.9
Gill, A.L.10
Heathcote, M.11
-
61
-
-
67649592285
-
A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours
-
Abs
-
Plummer ER, Calvert H, Arkenau H, Mallett KH, Squires M, Smith D, Lewis S, Judson I: A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol (2008) 26(15S): Abs 2519.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 S
, pp. 2519
-
-
Plummer, E.R.1
Calvert, H.2
Arkenau, H.3
Mallett, K.H.4
Squires, M.5
Smith, D.6
Lewis, S.7
Judson, I.8
-
62
-
-
67649936622
-
Activity of the multi-targeted kinase inhibitor, AT9283 on imatinib-resistant CML models
-
Tanaka R, Squires MS, Kimura S, Yokota A, Mallett K, Smyth T, Thompson NT, Nagao R, Yamauchi T, Ushiki T, Lyons JF et al: Activity of the multi-targeted kinase inhibitor, AT9283 on imatinib-resistant CML models. Blood (2008) 112(11):1104.
-
(2008)
Blood
, vol.112
, Issue.11
, pp. 1104
-
-
Tanaka, R.1
Squires, M.S.2
Kimura, S.3
Yokota, A.4
Mallett, K.5
Smyth, T.6
Thompson, N.T.7
Nagao, R.8
Yamauchi, T.9
Ushiki, T.10
Lyons, J.F.11
-
63
-
-
67649610475
-
ENMD-2076, an oral Aurora-A and angiogenesis kinase inhibitor
-
April
-
Bray MR: ENMD-2076, an oral Aurora-A and angiogenesis kinase inhibitor. Proceedings of the AACR Annual Meeting (2008) 99: 13 April.
-
(2008)
Proceedings of the AACR Annual Meeting
, vol.99
, Issue.13
-
-
Bray, M.R.1
-
64
-
-
67649917935
-
ENMD-2076 exerts antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models
-
Tentler JJ, Pierce ELB, Serkova NJ, Pitts TM, Bray MR, Fletcher GC, Eckhardt SG: ENMD-2076 exerts antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models. EJC Supplements (2008) 6(12):92.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 92
-
-
Tentler, J.J.1
Pierce, E.L.B.2
Serkova, N.J.3
Pitts, T.M.4
Bray, M.R.5
Fletcher, G.C.6
Eckhardt, S.G.7
-
65
-
-
67649943593
-
An open-label, dose-escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer
-
Abs
-
Bastos BR, Diamond J, Hansen R et al: An open-label, dose-escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer. J Clin Oncol (2009) 27:Abs 3520
-
(2009)
J Clin Oncol
, vol.27
, pp. 3520
-
-
Bastos, B.R.1
Diamond, J.2
Hansen, R.3
-
66
-
-
67649955245
-
The novel Aurora kinase inhibitor AS703569 shows potent anti-tumor activity in acute myelogenous leukemia (AML)
-
Abs
-
Romanelli A, Shaw J, Spooner E, Ma J, Clark A: The novel Aurora kinase inhibitor AS703569 shows potent anti-tumor activity in acute myelogenous leukemia (AML). Proceedings of the AACR Annual Meeting (2007) 98: Abs 1817.
-
(1817)
Proceedings of the AACR Annual Meeting
, vol.98
-
-
Romanelli, A.1
Shaw, J.2
Spooner, E.3
Ma, J.4
Clark, A.5
-
67
-
-
67649893048
-
Preclinical evaluation of the orally available Aurora kinase inhibitor AS703569 to support the selection of tumor indications for clinical studies
-
Abs
-
Maier A, Schuler J, Bausch N, Fiebig H, Romanelli A, Gianella-Borradori A: Preclinical evaluation of the orally available Aurora kinase inhibitor AS703569 to support the selection of tumor indications for clinical studies.Proceedings of the AACR Annual Meeting (2007) 98: Abs 3264.
-
(2007)
Proceedings of the AACR Annual Meeting
, vol.98
, pp. 3264
-
-
Maier, A.1
Schuler, J.2
Bausch, N.3
Fiebig, H.4
Romanelli, A.5
Gianella-Borradori, A.6
-
68
-
-
67649905530
-
Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of Aurora and other kinases, administered orally in patients with advanced hematological malignancies
-
Sonet A, Graux C, Maertens J, Hartog CM, Duyster J, Götze K, Greiner J, Hütter ML, Gratwohl A, Heim D, Hess D et al: Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of Aurora and other kinases, administered orally in patients with advanced hematological malignancies. Blood (2008) 112(11):2963.
-
(2008)
Blood
, vol.112
, Issue.11
, pp. 2963
-
-
Sonet, A.1
Graux, C.2
Maertens, J.3
Hartog, C.M.4
Duyster, J.5
Götze, K.6
Greiner, J.7
Hütter, M.L.8
Gratwohl, A.9
Heim, D.10
Hess, D.11
-
69
-
-
33947174540
-
-
Rigel Pharmaceuticals Inc: Rigel announces start of phase 1 combination therapy study of R763/AS703569 in advanced malignancies, July 12
-
Rigel Pharmaceuticals Inc: Rigel announces start of phase 1 combination therapy study of R763/AS703569 in advanced malignancies. Press Release (2007): July 12.
-
(2007)
Press Release
-
-
-
70
-
-
65649154573
-
Preliminary results of a phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors
-
Schöffski P, Dumez H, Jones SF, Fowst C, Gerletti P, Xu H, Jakubczak J, Infante J, Mellaerts N, Burris HA: Preliminary results of a phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors. EJC Supplements (2008) 6(12):91.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 91
-
-
Schöffski, P.1
Dumez, H.2
Jones, S.F.3
Fowst, C.4
Gerletti, P.5
Xu, H.6
Jakubczak, J.7
Infante, J.8
Mellaerts, N.9
Burris, H.A.10
-
71
-
-
67650039331
-
Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2
-
Abs
-
Griffiths G, Scaerou F, Midgley C, McClue S, Tosh C, Jackson W, MacCallum D, Wang S, Fischer P, Glover D: Anti-tumor activity of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. Proceedings of the AACR Annual Meeting(2008) 99: Abs 5644.
-
(2008)
Proceedings of the AACR Annual Meeting
, vol.99
, pp. 5644
-
-
Griffiths, G.1
Scaerou, F.2
Midgley, C.3
McClue, S.4
Tosh, C.5
Jackson, W.6
MacCallum, D.7
Wang, S.8
Fischer, P.9
Glover, D.10
-
72
-
-
67649920285
-
-
Hajduch M, Vydra D, Dzubak P, Dziechciarkova M, Stuart I, Zheleva D: In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. Proceedings of the AACR Annual Meeting (2008) 99: Abs 5645.
-
Hajduch M, Vydra D, Dzubak P, Dziechciarkova M, Stuart I, Zheleva D: In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. Proceedings of the AACR Annual Meeting (2008) 99: Abs 5645.
-
-
-
-
73
-
-
67649943599
-
-
Taverna P, Hogan J, Kumer J, Arbitrano J, Hoch U, Silverman J, Howlett A: SNS-314, a potent inhibitor of Aurora kinases, shows broad anti-tumor activity and dosing flexibility in vivo. Ann Oncol (2007) 18(Suppl 4):iv33.
-
Taverna P, Hogan J, Kumer J, Arbitrano J, Hoch U, Silverman J, Howlett A: SNS-314, a potent inhibitor of Aurora kinases, shows broad anti-tumor activity and dosing flexibility in vivo. Ann Oncol (2007) 18(Suppl 4):iv33.
-
-
-
-
74
-
-
67649924995
-
Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients
-
Robert F, Hurwitz H, Uronis H, Verschraegen C, Advani R, Chen A, Messerschmidt GL, Havrilla N, Taverna P, Evanchik M: Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients. EJC Supplements (2008) 6(12):91-92.
-
(2008)
EJC Supplements
, vol.6
, Issue.12
, pp. 91-92
-
-
Robert, F.1
Hurwitz, H.2
Uronis, H.3
Verschraegen, C.4
Advani, R.5
Chen, A.6
Messerschmidt, G.L.7
Havrilla, N.8
Taverna, P.9
Evanchik, M.10
-
75
-
-
58149496571
-
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells
-
Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS: Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.J Transl Med (2008) 6:79.
-
(2008)
J Transl Med
, vol.6
, pp. 79
-
-
Scharer, C.D.1
Laycock, N.2
Osunkoya, A.O.3
Logani, S.4
McDonald, J.F.5
Benigno, B.B.6
Moreno, C.S.7
-
76
-
-
44949157910
-
-
Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S: Molecular basis of drug resistance in Aurora kinases.Chem Biol (2008) 15(6):552-562. · Reports the first observed resistance against Aurora kinase inhibitors caused by mutations in Aurora B.
-
Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, Taylor S: Molecular basis of drug resistance in Aurora kinases.Chem Biol (2008) 15(6):552-562. · Reports the first observed resistance against Aurora kinase inhibitors caused by mutations in Aurora B.
-
-
-
|